EZH2 in normal hematopoiesis and hematological malignancies

Laurie Herviou; Giacomo Cavalli; Guillaume Cartron; Bernard Klein; Jérôme Moreaux

doi:10.18632/oncotarget.6198

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

EZH2 in normal hematopoiesis and hematological malignancies

Laurie Herviou _, Giacomo Cavalli, Guillaume Cartron, Bernard Klein and Jérôme Moreaux

PDF | HTML | How to cite

Oncotarget. 2016; 7:2284-2296. https://doi.org/10.18632/oncotarget.6198

Metrics: PDF 4845 views | HTML 4365 views | ?

Abstract

Laurie Herviou2, Giacomo Cavalli2, Guillaume Cartron3,4, Bernard Klein1,2,3 and Jérôme Moreaux1,2,3

1 Department of Biological Hematology, CHU Montpellier, Montpellier, France

2 Institute of Human Genetics, CNRS UPR1142, Montpellier, France

3 University of Montpellier 1, UFR de Médecine, Montpellier, France

4 Department of Clinical Hematology, CHU Montpellier, Montpellier, France

Correspondence to:

Jérôme Moreaux, email:

Keywords: hematological malignancies, EZH2, Polycomb complex, therapeutic target

Received: August 07, 2015 Accepted: October 14, 2015 Published: October 20, 2015

Abstract

Enhancer of zeste homolog 2 (EZH2), the catalytic subunit of the Polycomb repressive complex 2, inhibits gene expression through methylation on lysine 27 of histone H3. EZH2 regulates normal hematopoietic stem cell self-renewal and differentiation. EZH2 also controls normal B cell differentiation. EZH2 deregulation has been described in many cancer types including hematological malignancies. Specific small molecules have been recently developed to exploit the oncogenic addiction of tumor cells to EZH2. Their therapeutic potential is currently under evaluation. This review summarizes the roles of EZH2 in normal and pathologic hematological processes and recent advances in the development of EZH2 inhibitors for the personalized treatment of patients with hematological malignancies.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 6198

Publication Alerts

Reviews:

EZH2 in normal hematopoiesis and hematological malignancies

Abstract